Otsuka Pharmaceutical Development & Commercialization
Presença
Otsuka Holdings é uma das ...
Otsuka Holdings é uma empresa listada sob o símbolo 4578 (JP).
Otsuka Holdings tem presença direta em 10 países.Otsuka Holdings possui 25 subsidiárias incluindo Astex, Astex Pharmaceuticals e Cambridge Isotope Laboratories.
Eles estão dentro:
- Farmacêutica54%
- Equipamentos Médicos27%
- Outro19%
Executivos
Veja o organograma con seus 3 executivos principais
Biografias mais buscadas da Otsuka Pharmaceutical Development & Commercialization
- William Carson, Chairman of the Board
- Al D'Alonzo, Vice President, Promotional Compliance
- Nina Spiller, Vice President, Clinical Management
Criar um alerta
para seguir os movimentos de executivos da Otsuka Pharmaceutical Development & Commercialization.
Farmacêutica
Otsuka Holdings possui 1.863 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Otsuka Pharmaceutical Development & Commercialization
- Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease | Otsuka US
- FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults | Otsuka US
- Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder | Otsuka US
- Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia | Otsuka US
- Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder | Otsuka
- Otsuka and Verily Expand Collaboration on Novel Clinical Trials Solutions to Accelerate Research in Major Depressive Disorder | Otsuka US
- Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia | Otsuka US
- Otsuka Pharmaceutical and Lundbeck Present Positive Data From Multiple Phase 3 Studies Showing Brexpiprazole Significantly Improved Symptoms of Agitation in Patients with Alzheimer's Dementia at the 2022 Clinical Trials for Alzheimer’s Disease Congress |
- Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder | Otsuka US
- Avanir Pharmaceuticals, Inc. Business Will Be Integrated Into Otsuka America Pharmaceutical, Inc. as of January 1, 2023 | Otsuka US
- View more press releases Close
Redes sociais sobre Otsuka Pharmaceutical Development & Commercialization
- Otsuka Pharmaceutical Development & Commercialization na Wikipedia, Google News e Yahoo Finance
- Otsuka Pharmaceutical Development & Commercialization na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo William Carson 
Ligue para a Otsuka Pharmaceutical Development & Commercialization em +1 609...
